Steven Potts, PhD, MBA, chairs the Drug Development Council (volunteer) for the International Cancer Advocacy Network, a non-profit working to match new therapeutic medicines to cancer patients by their molecular profiles. He founded the multi-armed immunotherapy company, OncoMyx, in 2018 and raised $75M total of venture funding. Previously, he was Vice President of Medical Affairs at Ignyta, which was acquired by Roche/Genentech in 2017, and he led the global operation of the testing of over 20,000 patients inan oncology basket trial for entrectinib in 15 countries. He has been a founder and executive in multiple successful startups and exits in the oncology area. He testified in Congress in 2023 regarding the damage the Inflationary Reduction Act has been causing to innovation with the 'small molecule penalty'.